Dr. Rexer is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3601 The Vanderbilt Clinic
Nashville, TN 37232Phone+1 615-936-2000Fax+1 615-343-3212
Education & Training
Vanderbilt University Medical CenterFellowship, Hematology and Medical Oncology, 2005 - 2009- Vanderbilt University Medical CenterResidency, Internal Medicine, 2003 - 2005
Vanderbilt University School of MedicineClass of 2003
Certifications & Licensure
TN State Medical License 2005 - 2025
AL State Medical License 2020 - 2020- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
- American Board of Obesity Medicine Obesity Medicine
Clinical Trials
- Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer Start of enrollment: 2014 May 01
- Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer Start of enrollment: 2017 Jan 18
- A 2-Week Ketogenic Diet in Combination With Letrozole to Modulate PI3K Signaling in ER+ Breast Cancer Start of enrollment: 2019 Jul 08
Publications & Presentations
PubMed
- 1 citationsFeasibility and Tolerability of Adjuvant Capecitabine-Based Chemoradiation in Patients With Breast Cancer and Residual Disease After Neoadjuvant Chemotherapy: A Prospe...Meridith L Balbach, Alexander D Sherry, Brent N Rexer, Vandana G Abramson, Kenneth J Niermann
International Journal of Radiation Oncology, Biology, Physics. 2024-04-01 - 4 citationsA Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer.Jamunarani Veeraraghavan, Carolina Gutierrez, Carmine De Angelis, Robert Davis, Tao Wang
Clinical Cancer Research. 2023-08-15 - 2 citationsObesity and metabolic syndrome are associated with short-term endocrine therapy resistance in early ER + breast cancer.Riley Bergman, Yvonne A Berko, Violeta Sanchez, Melinda E Sanders, Paula I Gonzalez-Ericsson
Breast Cancer Research and Treatment. 2023-01-01
Press Mentions
Grant Strengthens Breast Cancer Research EffortsAugust 22nd, 2019
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
